Document Detail

Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
MedLine Citation:
PMID:  20138360     Owner:  NLM     Status:  MEDLINE    
Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome 13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM.
Ji Yuan; Radhika Shah; Anita Kulharya; Celalettin Ustun
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Leukemia research     Volume:  34     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-24     Completed Date:  2010-06-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  954-7     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Department of Pathology, Medical College of Georgia, Augusta, GA 30912, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / pharmacology*,  therapeutic use
Antineoplastic Agents / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Boronic Acids / administration & dosage,  pharmacology*
Chromosome Deletion*
Chromosomes, Human, Pair 13
Chromosomes, Human, Pair 14 / ultrastructure
Chromosomes, Human, Pair 8 / ultrastructure
Clone Cells / drug effects,  ultrastructure
Combined Modality Therapy
Dexamethasone / administration & dosage
Drug Resistance, Neoplasm / genetics*
Middle Aged
Multiple Myeloma / drug therapy,  genetics*,  pathology,  surgery
Neoplastic Stem Cells / drug effects*,  ultrastructure
Peripheral Blood Stem Cell Transplantation
Protease Inhibitors / pharmacology*,  therapeutic use
Pyrazines / administration & dosage,  pharmacology*
Thalidomide / administration & dosage,  analogs & derivatives*,  pharmacology
Translocation, Genetic
Transplantation, Autologous
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib; 191732-72-6/lenalidomide; 50-02-2/Dexamethasone; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients...
Next Document:  Cadmium impairs mineral and carbohydrate mobilization during the germination of bean seeds.